Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
Authors:
Open Access
- 1 December 2019
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 3 (3) , 1-6
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Immunophenotypic analysis of T‐acute lymphoblastic leukemia. A CD5‐based ETP‐ALL perspective of non‐ETP T‐ALLEuropean Journal of Haematology, 2014
- Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemiaLeukemia, 2013
- Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid LeukemiaCancer Discovery, 2013
- Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemiaFrontiers of Medicine, 2012
- Clinical significance of early T‐cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99‐15British Journal of Haematology, 2011
- T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)Blood, 2009
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemiaThe Lancet Oncology, 2009
- Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Blood, 2007
- Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma CellsCancer Research, 2005
- Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemiaCancer, 2004